Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation

European Journal of Cancer

Volumn 39, Issue 5, 2003, Pages 675-683

  Moneta, D ^a   Geroni, C ^a   Valota, O ^a   Grossi, P ^a   De Jonge, M J A ^b   Brughera, M ^a   Colajori, E ^a   Ghielmini, M ^c   Sessa, C ^c  

^a Pharmacia Corporation   (Italy)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

Cytotoxic; IC90 ratios; In vitro myelotoxicity; PNU 159548

Indexed keywords

4 DEMETHOXY 3' DEAMINO 3' AZIRIDINYL 4' METHYLSULFONYLDAUNORUBICIN; ANTINEOPLASTIC AGENT; DRUG METABOLITE; PNU 159548; PNU 169884; UNCLASSIFIED DRUG; 4-DEMETHOXY-3'-DEAMINO-3'-AZIRIDINYL-4'-METHYLSULFONYLDAUNORUBICIN; DAUNORUBICIN; DRUG DERIVATIVE;

ACCURACY; ANEMIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW CELL; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CLONOGENIC ASSAY; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN CELL; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG SCREENING; HEMATOPOIETIC STEM CELL; MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DAUNORUBICIN; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICE; THROMBOCYTOPENIA; TUMOR STEM CELL ASSAY;

EID: 0037334598     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00812-2     Document Type: Article

References (21)

1. Collins J.M., Zaharko D.S., Dedrick R.L., Chabner B.A. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep. 70:1986;73-80.
2. Collins J.M., Grieshaber C.K., Chabner B.A. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Nat. Cancer Inst. 82:1990;1321-1326.
3. Parchment R.E., Huang M., Erickson-Miller C.L. Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol. Pathol. 21:1993;241-250.
4. Parchment R.E., Gordon M., Grieshaber C.K., Sessa C., Volpe D., Ghielmini M. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann. Oncol. 9:1998;357-364.
5. Geroni C., Ripamonti M., Arrigoni C.et al. Pharmacological and toxicological aspects of PNU-159548. a novel antineoplastic agent Cancer Res. 61:2001;1983-1990.
6. Marchini S., Gonzalez Paz O., Ripamonti M.et al. Sequence-specific DNA interactions by novel alkylating anthracycline derivatives. Anti-Cancer Drug Des.ign. 10:1995;641-653.
7. Ripamonti M., Farao M., Rossi R., Geroni C. Synergistic antitumor effect of PNU-159548 in combination with CPT-11 against murine leukemia and human tumor models. Proc. Am. Assoc. Cancer Res. 40:1999;589.
8. Geroni C., Ripamonti M., Rossi R., Trizio D. Synergistic combinations of PNU-159548 with other antitumor drugs. Proc. 11th NCI-EORTC-AACR Symp. New Drugs in Cancer Ther. A364:2000;116.
9. Marchini S., Damia G., Broggini M.et al. PNU-159548, a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Cancer Res. 61:2001;1991-1995.
10. Schott B., Robert J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem. Pharmacol. 38:1989;4069-4074.
11. De Jonge MJA, Verweij J, Van der Gaast A, et al. Phase I and pharmacokinetic studies on PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumors. Eur J Cancer 2002, 38, 2407-2415.
12. Parchment R.E., Volpe D.A., Lorusso P.M., Erickson-Miller C.L., Murphy M.J., Grieshaber C.K. In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine and canine marrow. J. Nat. Cancer Inst. 86:1994;273-280.
13. Ghielmini M., Colli E., Bosshard G.et al. Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites. Cancer Chemother. Pharmacol. 42:1998;235-240.
14. Ghielmini M., Bosshard G., Capolongo L.et al. Estimation of the haematological toxicity of a minor groove alkylators using tests on human cord blood cells. Br. J. Cancer. 75:1997;878-883.
15. Hogge D., Fanning S., Bockhold K.et al. Quantitation and characterization of human megakaryocyte colony-forming cells using a standardized serum-free assay. Br. J. Haematol. 96:1997;790-800.
16. Lewis J.L., Blackett N.M., Gordon M.Y. The kinetics of colony formation by CFU-GM in vitro. Br. J. Haematol. 88:1994;440-442.
17. Ings R.M. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica. 20:1990;1201-1231.
18. Erickson-Miller C.L., May R.D., Tomaszewski J.et al. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother. Pharmacol. 39:1997;467-472.
19. Volpe D.A., Tomaszewski J.E., Parchment ?.et al. Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells. Cancer Chemother. Pharmacol. 39:1996;143-149.
20. Pessina, A, Abella B, Bueren J, et al. Method development for prevalidation study of the in vitro GM-CFU assay for predicting myelotoxicity. In Balls M, Van Zeller AM, Halder ME, eds. Progress in the Reduction, Refinement and Replacement of Animal Experimentation. 2000, 679-692.
21. Pessina ?. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocytes/macrophage (CFU-GM) assay. Toxicology in Vitro. 15:2001;729-740.